Moonwalk Biosciences has announced the closure of its $70 million Series B financing round. This funding will support the advancement of their innovative RNAi therapies targeting adipose tissue. The investment aims to tackle obesity and cardiometabolic diseases. The financing round marked a significant milestone in their continued development efforts.
Who to call at Moonwalk Biosciences, and when
A new round usually means Moonwalk Biosciences is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Moonwalk Biosciences raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Moonwalk Biosciences, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Moonwalk Biosciences
Location
2 TOWER PLACE, 17TH FLOOR
San Francisco, California, United States
About
Moonwalk Biosciences is an early-stage therapeutics company co-founded by Dr. Feng Zhang and leading experts in cell state epigenetics including Alex Aravanis, the former CTO of Illumina. The company has developed a differentiated approach to mapping the epigenome of cellular states at the whole genome, single cell resolution level, as well as proprietary strategies for precise epigenetic engineering. The combination enables both a novel discovery platform and a path to developing therapeutics that include both epigenetic engineering and other traditional modalities.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Moonwalk Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San FranciscoBiotechnology